Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
(NASDAQ:TVGN) WARREN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the continuing need for SARS-CoV-2 treatments for individuals with weakened immune systems, who are at the highest risk of complications from the virus. TVGN 489, the Company’s investigational allogeneic SARS-CoV-2-specific Cytotoxic CD8+ T lymphocyte (CTL) immunotherapy is developed using the ExacTcell platform. It is designed to fortify anti-SARS-CoV-2 immunity in these individuals and directly eliminate the virus. The CTLs are directed against the entire viral genome rather than single protein. Publication of positive POC/dose finding clinical trial data of TVGN 489 is available through Blood Advances:
Related Questions
How will the release of TVGN 489's positive trial data affect Tevogen's imminent stock price movement?
What is the expected timeline for FDA review or approval of TVGN 489, and how does it compare to competing SARS‑CoV‑2 immunotherapies?
What potential revenue and market share could Tevogen capture in the niche of immunocompromised patients if TVGN 489 is approved?